IRIS
SANTANTONIO, TERESA ANTONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.198
NA - Nord America 9.525
AS - Asia 6.433
Continente sconosciuto - Info sul continente non disponibili 69
SA - Sud America 21
AF - Africa 14
OC - Oceania 14
Totale 28.274
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.481
CN - Cina 4.305
IE - Irlanda 4.161
UA - Ucraina 3.147
SE - Svezia 1.699
IN - India 894
FR - Francia 876
IT - Italia 867
FI - Finlandia 666
TR - Turchia 655
SG - Singapore 394
DE - Germania 292
GB - Regno Unito 271
VN - Vietnam 122
AT - Austria 88
EU - Europa 68
RU - Federazione Russa 30
CA - Canada 29
CZ - Repubblica Ceca 25
BE - Belgio 22
NL - Olanda 19
MX - Messico 14
AU - Australia 11
PK - Pakistan 10
ES - Italia 9
HK - Hong Kong 9
IR - Iran 9
JP - Giappone 9
EG - Egitto 7
SY - Repubblica araba siriana 7
UY - Uruguay 7
CL - Cile 5
RO - Romania 5
BR - Brasile 4
CH - Svizzera 4
PT - Portogallo 4
SA - Arabia Saudita 4
AR - Argentina 3
BG - Bulgaria 3
KR - Corea 3
NZ - Nuova Zelanda 3
RS - Serbia 3
TH - Thailandia 3
GH - Ghana 2
GR - Grecia 2
MY - Malesia 2
PE - Perù 2
PS - Palestinian Territory 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BJ - Benin 1
DK - Danimarca 1
ID - Indonesia 1
IQ - Iraq 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LV - Lettonia 1
MK - Macedonia 1
ML - Mali 1
PA - Panama 1
PL - Polonia 1
Totale 28.274
Salva come PNG Salva come JPEG
Città #
Dublin 4.159
Jacksonville 2.223
Dearborn 1.306
Chandler 1.218
Nanjing 1.158
Nyköping 877
Wilmington 661
Beijing 478
Princeton 477
Nanchang 444
San Mateo 370
Shenzhen 301
Helsinki 263
Shenyang 258
Ann Arbor 222
Singapore 220
Tianjin 185
Kunming 178
Hebei 168
Ashburn 154
Jiaxing 140
Changsha 139
Hilden 133
Des Moines 127
Dong Ket 117
Boardman 95
Hangzhou 95
Stevenage 88
Vienna 85
Ningbo 79
Jinan 77
Bari 73
Woodbridge 73
Guangzhou 66
Lanzhou 59
Zhengzhou 59
New York 55
Foggia 54
Los Angeles 51
Shanghai 48
Changchun 37
Munich 36
Taizhou 35
London 31
Orange 30
Rome 27
Pune 26
Redwood City 24
Norwalk 23
Auburn Hills 20
Borås 20
Hefei 20
Brussels 19
Wuhan 19
Brno 18
Philadelphia 18
Milan 16
Rockville 16
Chengdu 14
Fuzhou 14
Washington 13
Chicago 12
Seattle 11
Falls Church 10
Jinhua 10
Meda 10
San Severo 10
Acquaviva Delle Fonti 9
Ankara 9
Redmond 9
Saint Petersburg 9
Toronto 9
Augusta 8
Cutrofiano 8
Fairfield 8
Kocaeli 8
Tokyo 8
Gioia Del Colle 7
Hanover 7
Leawood 7
Marano Di Napoli 7
Montevideo 7
San Jose 7
Bitonto 6
Florence 6
Hidalgo 6
Lincoln 6
Madrid 6
Olomouc 6
Palermo 6
Paris 6
Torremaggiore 6
Trieste 6
Andover 5
Central 5
Gunzenhausen 5
Haikou 5
Hanoi 5
Melbourne 5
Mountain View 5
Totale 17.794
Salva come PNG Salva come JPEG
Nome #
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. 357
Diagnosi rapida di sepsi: emocoltura e multiplex real time PCR a confronto 350
Epatite cronica anti-HBe/HBV DNA positiva e mutanti pre-core del virus dell'epatite B 176
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 155
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 126
HCV-related mixed cryoglobulinemia: data from PITER, a nationwide italian HCV cohort study 116
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 114
TERAPIA DELL'EPATITE ACUTA B e C 109
Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort 109
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 107
Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. 105
National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing 102
Efficacy of a 24-week course of PEG-Interferon a-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. 99
Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. 99
Mucormicosi rino-orbitaria: una patologia da tenere d'occhio 99
Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic epatiti B 95
Natural course of acute hepatitis C: a long-term prospective study 94
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 94
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 94
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features 93
Tipizzazione fenotipica di Klebsiella Pneumoniae MDR mediante MALDI-TOFS MS in isolati clinici della Rianimazione A.O.U. OO. RR. Foggia 93
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 92
Clinical and virological features of Hepatitis B and Delta infections in anti-HIV carriers 92
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 92
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant Chronic Hepatitis B 91
The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? 90
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 90
Comparison between HCV RNA and E1/E2 antibodies in patients on IFN treatment 90
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 90
Chronic viral hepatitis in patients with beta-thalassaemia minor. 87
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. 86
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 86
Possible mechanisms involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. 85
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 85
Flares during long-term entecavir therapy in chronic hepatitis B 85
Non-A,non-B hepatitis virus. 84
Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. 82
Clinical value of HIV p24 Ag in cerebrospinal fluid of symptomatic or asymptomatic HIV-infected patients 82
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 82
Correlation between knowledge on transmission and prevention of HIV/STI and proficiency in condom use among male migrants from Africa and Middle East evaluated by a Condom Use Skills score using a wooden penile model. 82
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 82
Feasibility of vaccination in preventing secondary cases of hepatitis A virus infection. 81
Lack of HBV and HDV replicative activity in HBsAg-positive intravenous drug addicts with immune deficiency due to HIV. 81
HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY 81
Acute hepatitis C: current status and remaining challenges. 80
Determinazione immunoenzimatica delle IgA specifiche anti-HAV nella diagnosi sierologica dell'epatite A 80
Diagnosi sierologica dell'epatite acuta da virus A. Messa a punto e valutazione di tre metodiche per la determinazione delle IgM specifiche anti-HAV 80
RIELISA: a new principle for the simultaneous detection of total and IgM antibodies. Application to hepatitis diagnosis 80
Hepatitis B core antigen expression in chronic hepatitis B: correlation with serum HBV DNA detected by a biotinylated probe 80
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 80
LE VARIANTI GENOMICHE DELLA REGIONE PRE-CORE DEL VIRUS DELL'EPATITE B: ASPETTI PATOGENETICI E CLINICI 80
Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation 79
Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. 79
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 79
Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. 78
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 78
Role of HCV infection in the development of carotid atherosclerosis in a cohort of HIV-infected patients 78
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 78
Lamivudine/Interferon combination therapy in anti-HBe positive chronic hepatitis B patients; a controlled pilot study. 77
Association of HCV-specific -interferon producing CD8+ T cells with viral clearance in acute hepatitis C 77
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF) 77
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 77
Dendritic Cell Maturation in HCV Infection: Altered Regulation of MHC Class I Antigen Processing-Presenting Machinery 76
Predominance of HBV genotype D/HDV genotype 1 among chronically infected drug abusers in Italy 76
Selection of a secretion incompetent mutant in the serum of a patient with severe hepatitis B 75
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues 75
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. 75
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 75
Long-term outcome of patients with HCV-related, Child’s class A cirrhosis treated with interferon-alpha (IFN): the impact of sustained virologic response (SVR) on hepatocellular carcinoma (HCC) occurrence and mortality 75
Male gender, genotype 3, previous alcohol use, increased BMI, and diabetes are factors independently correlated to advanced HCV chronic liver disease in Italy: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort study 75
Treatment of acute hepatitis C with interferon alfa-2b. 74
Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance. 74
Long-term response to interferon therapy in hepatitis B virus (HBV) pre-C mutants associated chronic hepatitis 74
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 74
Tocilizumab and corticosteroids for covid-19 treatment in elderly patients. Journal of Gerontology and Geriatrics 74
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. 73
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. 73
Valutazione di un test immunoenzimatico (ELISA) per la determinazione di un sistema Ag/Ab correlato all’epatite non-A,non-B post-trasfusionale 73
Association of primary hepatocellular carcinoma (PHC) and a non-A,non-B related antigen./antibody system detected by Enzyme Linked Immunosorbent Assay (ELISA) 73
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 73
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 73
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 73
Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease. 72
Virologic and clinical expression of reciprocal inhibitory effect of Hepatitis B, C, and Delta viruses in patients with chronic hepatitis 72
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 72
The course of anti-HBe/HBV-DNA positive chronic liver disease during long term lamivudine treatment 72
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 72
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. 72
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients 72
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. 71
High prevalence and heterogeneity of HBV pre-C mutants in anti-HBe-positive carriers with chronic liver disease in Southern Italy. 71
The use of molecular assays in the management of viral hepatitis. 71
Dosaggio radioimmunologico dell’HAV e delle IgA anti-HAV nelle feci di pazienti con epatite acuta di tipo A 71
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C 71
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 71
Clinical and histological outcome of extended lamivudine in patients with HBeAg negative chronic hepatitis B 71
Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 70
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 70
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 70
Clinical and virological features of HBV and HDV chronic hepatitis in subjects with HIV infection 70
Totale 8.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 153.968
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 153.968
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.070 0 0 0 0 863 851 900 109 570 105 604 68
2020/20213.834 546 22 478 32 482 101 534 98 544 520 174 303
2021/20222.615 388 21 36 70 341 129 69 234 310 297 102 618
2022/20238.196 950 196 274 370 335 603 32 474 4.613 126 124 99
2023/20241.238 178 61 365 41 83 182 98 61 8 18 13 130
2024/2025619 329 40 69 133 48 0 0 0 0 0 0 0
Totale 29.564